BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.
You may also be interested in...
Industry leaders at a PhRMA briefing talked about the unprecedented level of partnership going into developing COVID-19 vaccines and treatments – not to mention making enough of them.
M&A activity faces numerous hurdles during the COVID-19 pandemic but companies are finding different ways to negotiate, conduct due diligence and get deals completed, BIO 2020 speakers said.
The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.